This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.81% per year. These returns cover a period from January 1, 1988 through November 3, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
medical: Archive
Hims & Hers Scales Technology-Driven Care as Profitability Evolves
by Debanjana Dey
HIMS scales personalized care, expands globally and invests in technology as it balances growth with evolving profitability.
GDRXPositive Net Change HIMSNegative Net Change TEMNegative Net Change
medical medical-devices
BD Expands BD MAX With IVDR-Approved VIASURE Tests in Europe
by Zacks Equity Research
BDX expands its BD MAX menu in Europe with IVDR-approved respiratory and STI assays, boosting system utility and reinforcing its diagnostics growth strategy.
BDXNegative Net Change CAHNegative Net Change COONegative Net Change BTSGPositive Net Change
immuno-therapy medical medical-devices
SNY Stock Down on Double Trouble With Multiple Sclerosis Drug
by Zacks Equity Research
Sanofi shares slide after the FDA again delays its review of its MS drug tolebrutinib, and a phase III study fails to hit its primary endpoint.
SNYNegative Net Change ANIPNegative Net Change CRMDPositive Net Change
biotechs medical pharmaceuticals
The Longevity Shift: Healthcare REITs to Benefit From Global Aging
by Urmimala Biswas
WELL, VTR, CTRE and OHI are tapping the longevity economy as aging populations drive rising demand for senior housing, skilled nursing and long-term care real estate.
VTRNo Net Change OHINegative Net Change CTRENegative Net Change WELLPositive Net Change
finance healthcare medical medical-devices
KYTX Stock Rallies 23% on Upbeat Stiff Person Syndrome Study Data
by Zacks Equity Research
Kyverna Therapeutics shares jump 23% after a registrational phase II study of miv-cel meets primary and all secondary efficacy goals for treating stiff person syndrome.
ANIPNegative Net Change CRMDPositive Net Change CSTLNegative Net Change KYTXNegative Net Change
biotechnology biotechs medical pharmaceuticals
CHMP Backs EU Approval of MRNA's New COVID-19 Vaccine mNexspike
by Zacks Equity Research
CHMP backs EU approval of Moderna's next-generation mNexspike COVID-19 vaccine, with a final European Commission decision expected shortly.
MRNANegative Net Change ANIPNegative Net Change CRMDPositive Net Change CSTLNegative Net Change
biotechnology biotechs medical pharmaceuticals vaccines
Tempus AI Revenue Jumps 85% as Pricing Catalysts Line Up
by Urmimala Biswas
Tempus AI's Q3 revenue surged as oncology and hereditary testing led the way, margins improved, and pricing tailwinds and regulatory milestones took shape.
TXGNegative Net Change DOCSNegative Net Change TEMNegative Net Change
artificial-intelligence earnings-growth earnings-outlook healthcare medical medical-devices
How AbbVie's Pipeline Is Lining Up Key Product Launches
by Sundeep Ganoria
ABBV is lining up multiple late-stage launches, from Rinvoq label expansions to Parkinson???s and oncology assets nearing FDA decisions.
JNJNegative Net Change LLYNegative Net Change ABBVNegative Net Change
biotechs medical pharmaceuticals
GILD's Bictegravir and Lenacapavir Regimen for HIV Meets Primary Goal
by Zacks Equity Research
Gilead said its once-daily bictegravir/lenacapavir tablet met non-inferiority vs Biktarvy in phase III ARTISTRY-2, paving the way for filings.
GSKNegative Net Change GILDNegative Net Change FOLDPositive Net Change CRMDPositive Net Change
biotechnology biotechs medical pharmaceuticals
3 MedTech Stocks Poised to Gain in 2026 From the AI Boom
by Sridatri Sarkar
AI is reshaping MedTech, and Stryker, Tempus AI and GE HealthCare are emerging as key players leveraging AI across surgery, diagnostics and imaging.
SYKNegative Net Change NVDAPositive Net Change GEHCNegative Net Change TEMNegative Net Change
artificial-intelligence medical medical-devices
Is Phibro Animal Health Stock a Smart Addition to Your Portfolio Now?
by Zacks Equity Research
PAHC rides on strong Animal Health momentum, vaccine growth and emerging market demand, even as macro and competitive risks linger.
ILMNNegative Net Change PODDNegative Net Change PAHCNegative Net Change BTSGPositive Net Change
medical medical-devices
TMO Stock Set to Gain From the Expansion of Gibco Bacto Portfolio
by Zacks Equity Research
Thermo Fisher expands its Gibco Bacto CD portfolio with new formulations aimed at boosting E. coli-based plasmid DNA and protein production efficiency.
TMONegative Net Change ILMNNegative Net Change PODDNegative Net Change BTSGPositive Net Change
medical medical-devices
5 High Earnings Yield Value Picks Ahead of Key Economic Reports
by Rimmi Singhi
CRMD, CGAU, CMC, COMM and SHIP emerge as high earnings yield value picks as investors eye fundamentals ahead of key jobs and inflation reports.
CMCNegative Net Change COMMNegative Net Change CRMDPositive Net Change SHIPPositive Net Change CGAUPositive Net Change
basic-materials communications medical precious-metals transportation
Zacks Industry Outlook UnitedHealth, Humana and Centene
by Zacks Equity Research
UnitedHealth, Humana and Centene have been highlighted in this Industry Outlook article.
UNHNegative Net Change HUMNegative Net Change CNCNegative Net Change
medical
Do Options Traders Know Something About BMRN Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to BioMarin Pharmaceutical stock based on the movements in the options market lately.
BMRNNegative Net Change
medical
3 HMO Stocks in Focus Despite Rising Medical Costs, Regulatory Pressures
by Debasmita Chatterjee
The Medical-HMO industry pursues growth through M&A and tech innovation, aided by easing interest rates, but faces headwinds from rising medical costs, regulatory shifts and a shortage of healthcare professionals. UNH, HUM and CNC are likely to navigate industry storms.
UNHNegative Net Change HUMNegative Net Change CNCNegative Net Change
medical
Tempus AI Near $75 Target? Valuation, Upside and Risks
by Urmimala Biswas
Tempus AI's rally meets a $75 target. Here's how valuation, catalysts, risks, and key numbers set up the risk-reward into 2026.
TXGNegative Net Change DOCSNegative Net Change TEMNegative Net Change
artificial-intelligence healthcare medical medical-devices
FDA Approves J&J's Akeega for Expanded Use in Prostate Cancer
by Zacks Equity Research
JNJ secures FDA approval to expand Akeega into earlier-stage prostate cancer, backed by strong phase III data and a first-of-its-kind precision combo.
GSKNegative Net Change JNJNegative Net Change ANIPNegative Net Change CRMDPositive Net Change
biotechs medical
Abbott Gains From Lingo CGM's Expansion on Android Platform
by Zacks Equity Research
ABT expands its Lingo biowearable to Android, broadening access to real-time glucose tracking and pushing continuous monitoring into mainstream wellness.
ABTNegative Net Change BSXNegative Net Change ISRGNegative Net Change ATRCPositive Net Change
medical medical-devices
CHMP Backs Higher-Dose Wegovy as Novo Nordisk Seeks 2026 EU Approval
by Zacks Equity Research
NVO gains CHMP backing for a higher-dose Wegovy, paving the way for potential EU approval in 2026 as study data show stronger weight loss.
NVONegative Net Change LLYNegative Net Change VKTXNegative Net Change GPCRNegative Net Change
biotechnology biotechs medical pharmaceuticals
GSK's Nucala for COPD and Depemokimab for Asthma Get CHMP Nod in EU
by Zacks Equity Research
GSK gets CHMP backing for Nucala in COPD and depemokimab in asthma, setting up possible Europe approvals in 2026 for IL-5 therapies.
GSKNegative Net Change ANIPNegative Net Change CRMDPositive Net Change CSTLNegative Net Change
biotechs medical
BAX Highlights EMR-Integrated Smart Pumps Boost Patient Safety & Care
by Zacks Equity Research
Baxter shows EMR-integrated smart pumps cut safety alerts and speed IV setup, backed by real-world data from over a million infusions at ASHP 2025.
BSXNegative Net Change BAXNegative Net Change ISRGNegative Net Change MEDPNegative Net Change
medical medical-devices
RCUS Stock Down on Decision to Discontinue GILD Partnered Study
by Zacks Equity Research
Arcus halts the late-stage STAR-221 study for futility, dealing a setback to its domvanalimab program with Gilead. Stock down.
GILDNegative Net Change FOLDPositive Net Change CRMDPositive Net Change RCUSNegative Net Change
biotechnology biotechs medical pharmaceuticals
BMY Gains 13.1% in Three Months: Buy, Sell or Hold the Stock?
by Ekta Bagri
BMY shares are rebounding after a strong Q3, lifted by rising demand for Opdivo, Reblozyl and Camzyos, even as legacy drugs face generic pressure.
BMYNegative Net Change PFENegative Net Change MRKNegative Net Change
biotechs medical pharmaceuticals
CVS Stock Gains From Offering MMR Vaccine to South Carolina Residents
by Zacks Equity Research
CVS Health shares jump after the company begins offering MMR vaccines across South Carolina pharmacies and clinics post a measles outbreak.
OMCLPositive Net Change ILMNNegative Net Change CVSNegative Net Change BTSGPositive Net Change
medical